Nocdurna (Desmopressin Acetate) Patent Expiration, LOE Window & CMS Spending

Nocdurna (Desmopressin Acetate) by Antares: FDA Orange Book LOE 2030-04-13, 7 AB generics, $235K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAntares
FDA Application & PathwayN022517 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-04-13
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$235K
2024 Medicare Part D Spend$219K
2024 Medicaid Spend$16K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel